Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT01528254




Registration number
NCT01528254
Ethics application status
Date submitted
3/02/2012
Date registered
7/02/2012
Date last updated
24/09/2020

Titles & IDs
Public title
VERIFY:A Study to Compare Combination Regimen With Vildagliptin & Metformin Versus Metformin in Treatment-naïve Patients With Type 2 Diabetes Mellitus
Scientific title
A 5-year Study to Compare the Durability of Glycemic Control of a Combination Regimen With Vildagliptin & Metformin Versus Standard-of-care Monotherapy With Metformin, Initiated in Treatment-naïve Patients With Type 2 Diabetes Mellitus
Secondary ID [1] 0 0
2011-003712-23
Secondary ID [2] 0 0
CLAF237A23156
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Type 2 Diabetes Mellitus 0 0
Condition category
Condition code
Metabolic and Endocrine 0 0 0 0
Diabetes

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - vildagliptin
Treatment: Drugs - Metformin

Active comparator: Vilda 50mg bid + metformin - Metformin + vildagliptin

Experimental: Placebo + metformin - Metformin + Placebo of vildagliptin


Treatment: Drugs: vildagliptin
One tablet (50 mg oral) of vildagliptin in the morning and one tablet in the evening with or without food.

Treatment: Drugs: Metformin
Twice daily (bid) regimen during or after meals at the same time as vildagliptin.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Time to Initial Treatment Failure
Timepoint [1] 0 0
Visit 4 (Week 13) up to End of Study (Study Drug Discontinuation or Premature Subject Discontinuation)
Secondary outcome [1] 0 0
Rate of Loss in Glycemic Control During Period 1
Timepoint [1] 0 0
Visit 5 (Week 26) to End of Period 1
Secondary outcome [2] 0 0
Rate of Loss in Glycemic Control in HbA1c Over Time During Period 2
Timepoint [2] 0 0
From 26 weeks after start of Period 2 to end of Period 2
Secondary outcome [3] 0 0
Rate of Loss in Glycemic Control in Fasting Plasma Glucose (FPG) During Period 1
Timepoint [3] 0 0
Visit 5 (Week 26) to End of Period 1
Secondary outcome [4] 0 0
Rate of Loss in Glycemic Control in Fasting Plasma Glucose (FPG) Over Time During Period 2
Timepoint [4] 0 0
From 26 weeks after start of Period 2 to end of Period 2
Secondary outcome [5] 0 0
Rate of Loss of Beta Cell Function From Baseline to End of Study
Timepoint [5] 0 0
Visit 4 (Week 13), End of Period 1, End of Period 2, End of Study (Study Drug Discontinuation or Premature Subject Discontinuation)
Secondary outcome [6] 0 0
Rate of Change in Insulin Sensitivity From Baseline to End of Study
Timepoint [6] 0 0
Visit 4 (Week 13), End of Period 1, End of Period 2, End of Study (Study Drug Discontinuation or Premature Subject Discontinuation)
Secondary outcome [7] 0 0
Percentage of Participants With Adverse Events, Serious Adverse Events and Death
Timepoint [7] 0 0
From first dose of study treatment until End of Study (Study Drug Discontinuation or Premature Subject Discontinuation)

Eligibility
Key inclusion criteria
Key

* Type 2 Diabetes Mellitus (T2DM) diagnosed = 24 months ago
* glycosylated hemoglobin (HbA1c) =6.5% and =7.5% at Visit 1
* Treatment-naïve.
* Body mass index (BMI) =22 and =40 kg/m2 at Visit 1

Key
Minimum age
18 Years
Maximum age
70 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Pregnant or nursing (lactating) women
* Fasting plasma glucose (FPG) = 270 mg/dL (= 15.0 mmol/L)
* Previous or current participation in any vildagliptin clinical study.
* History of hypersensitivity to dipeptidyl peptidase-4 (DPP-4) inhibitors.
* Concurrent medical condition that may interfere with the interpretation of efficacy and safety data during the study.
* Donation of blood or significant blood loss equaling to at least one unit of blood within the past 2 weeks of start of study or a blood transfusion within the past 12 weeks or planned regular transfusions during the study period.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 4
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
30/03/2012
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
4/04/2019
Sample size
Target
Accrual to date
Final
2004
Recruitment in Australia
Recruitment state(s)
NSW,QLD
Recruitment hospital [1] 0 0
Novartis Investigative Site - Brookvale
Recruitment hospital [2] 0 0
Novartis Investigative Site - Woy Woy
Recruitment hospital [3] 0 0
Novartis Investigative Site - Morayfield
Recruitment postcode(s) [1] 0 0
2100 - Brookvale
Recruitment postcode(s) [2] 0 0
2256 - Woy Woy
Recruitment postcode(s) [3] 0 0
4506 - Morayfield
Recruitment outside Australia
Country [1] 0 0
Argentina
State/province [1] 0 0
Buenos Aires
Country [2] 0 0
Argentina
State/province [2] 0 0
Capital Federal
Country [3] 0 0
Argentina
State/province [3] 0 0
Cordoba
Country [4] 0 0
Argentina
State/province [4] 0 0
Corrientes
Country [5] 0 0
Austria
State/province [5] 0 0
Wien
Country [6] 0 0
Brazil
State/province [6] 0 0
CE
Country [7] 0 0
Brazil
State/province [7] 0 0
DF
Country [8] 0 0
Brazil
State/province [8] 0 0
GO
Country [9] 0 0
Brazil
State/province [9] 0 0
PA
Country [10] 0 0
Brazil
State/province [10] 0 0
PR
Country [11] 0 0
Brazil
State/province [11] 0 0
RS
Country [12] 0 0
Brazil
State/province [12] 0 0
SP
Country [13] 0 0
Bulgaria
State/province [13] 0 0
Gabrovo
Country [14] 0 0
Bulgaria
State/province [14] 0 0
Kazanlak
Country [15] 0 0
Bulgaria
State/province [15] 0 0
Plovdiv
Country [16] 0 0
Bulgaria
State/province [16] 0 0
Razgrad
Country [17] 0 0
Bulgaria
State/province [17] 0 0
Ruse
Country [18] 0 0
Bulgaria
State/province [18] 0 0
Smolian
Country [19] 0 0
Bulgaria
State/province [19] 0 0
Sofia
Country [20] 0 0
Colombia
State/province [20] 0 0
Bolivar
Country [21] 0 0
Colombia
State/province [21] 0 0
Cundinamarca
Country [22] 0 0
Colombia
State/province [22] 0 0
Baranquilla
Country [23] 0 0
Colombia
State/province [23] 0 0
Bogotá
Country [24] 0 0
Czechia
State/province [24] 0 0
Czech Republic
Country [25] 0 0
Czechia
State/province [25] 0 0
Brandys Nad Labem
Country [26] 0 0
Czechia
State/province [26] 0 0
Praha
Country [27] 0 0
Dominican Republic
State/province [27] 0 0
Republica Dominicana
Country [28] 0 0
Dominican Republic
State/province [28] 0 0
Santo Domingo
Country [29] 0 0
Estonia
State/province [29] 0 0
Saku
Country [30] 0 0
Estonia
State/province [30] 0 0
Tallinn
Country [31] 0 0
Finland
State/province [31] 0 0
Suomi
Country [32] 0 0
Finland
State/province [32] 0 0
Kerava
Country [33] 0 0
Finland
State/province [33] 0 0
Kouvola
Country [34] 0 0
Finland
State/province [34] 0 0
Tampere
Country [35] 0 0
Germany
State/province [35] 0 0
Hainburg
Country [36] 0 0
Germany
State/province [36] 0 0
Aschaffenburg
Country [37] 0 0
Germany
State/province [37] 0 0
Dresden
Country [38] 0 0
Germany
State/province [38] 0 0
Duesseldorf
Country [39] 0 0
Germany
State/province [39] 0 0
Essen
Country [40] 0 0
Germany
State/province [40] 0 0
Esslingen am Neckar
Country [41] 0 0
Germany
State/province [41] 0 0
Fulda
Country [42] 0 0
Germany
State/province [42] 0 0
Gelnhausen
Country [43] 0 0
Germany
State/province [43] 0 0
Kamp-Lintfort
Country [44] 0 0
Germany
State/province [44] 0 0
Koeln
Country [45] 0 0
Germany
State/province [45] 0 0
Ludwigshafen
Country [46] 0 0
Germany
State/province [46] 0 0
Neuwied
Country [47] 0 0
Germany
State/province [47] 0 0
Saint Ingbert - Oberwuerzbach
Country [48] 0 0
Germany
State/province [48] 0 0
Wangen
Country [49] 0 0
Guatemala
State/province [49] 0 0
Clinica
Country [50] 0 0
Guatemala
State/province [50] 0 0
Guatemala City
Country [51] 0 0
Hong Kong
State/province [51] 0 0
Hong Kong
Country [52] 0 0
Hong Kong
State/province [52] 0 0
HongKong
Country [53] 0 0
Hungary
State/province [53] 0 0
Zala
Country [54] 0 0
Hungary
State/province [54] 0 0
Budapest
Country [55] 0 0
Hungary
State/province [55] 0 0
Csongrad
Country [56] 0 0
Hungary
State/province [56] 0 0
Eger
Country [57] 0 0
Hungary
State/province [57] 0 0
Kalocsa
Country [58] 0 0
Hungary
State/province [58] 0 0
Szeged
Country [59] 0 0
Hungary
State/province [59] 0 0
Veszprem
Country [60] 0 0
India
State/province [60] 0 0
Delhi
Country [61] 0 0
India
State/province [61] 0 0
Karnataka
Country [62] 0 0
India
State/province [62] 0 0
Kerala
Country [63] 0 0
India
State/province [63] 0 0
Madhya Pradesh
Country [64] 0 0
India
State/province [64] 0 0
Maharashtra
Country [65] 0 0
India
State/province [65] 0 0
Rajasthan
Country [66] 0 0
India
State/province [66] 0 0
Tamil Nadu
Country [67] 0 0
India
State/province [67] 0 0
Tamilnadu
Country [68] 0 0
India
State/province [68] 0 0
Chandigarh
Country [69] 0 0
Israel
State/province [69] 0 0
Heifa
Country [70] 0 0
Israel
State/province [70] 0 0
Jerusalem
Country [71] 0 0
Israel
State/province [71] 0 0
Kfar Saba
Country [72] 0 0
Israel
State/province [72] 0 0
Rehovot
Country [73] 0 0
Israel
State/province [73] 0 0
Sefad
Country [74] 0 0
Israel
State/province [74] 0 0
Tel Aviv
Country [75] 0 0
Israel
State/province [75] 0 0
Tel Giborim, Holon
Country [76] 0 0
Italy
State/province [76] 0 0
BS
Country [77] 0 0
Italy
State/province [77] 0 0
CB
Country [78] 0 0
Italy
State/province [78] 0 0
GE
Country [79] 0 0
Italy
State/province [79] 0 0
MI
Country [80] 0 0
Italy
State/province [80] 0 0
PV
Country [81] 0 0
Italy
State/province [81] 0 0
RM
Country [82] 0 0
Korea, Republic of
State/province [82] 0 0
Gyeonggi-do
Country [83] 0 0
Korea, Republic of
State/province [83] 0 0
Korea
Country [84] 0 0
Korea, Republic of
State/province [84] 0 0
Seocho Gu
Country [85] 0 0
Korea, Republic of
State/province [85] 0 0
Daejeon
Country [86] 0 0
Korea, Republic of
State/province [86] 0 0
Incheon
Country [87] 0 0
Korea, Republic of
State/province [87] 0 0
Seoul
Country [88] 0 0
Latvia
State/province [88] 0 0
LV
Country [89] 0 0
Latvia
State/province [89] 0 0
Daugavpils
Country [90] 0 0
Latvia
State/province [90] 0 0
Riga
Country [91] 0 0
Lithuania
State/province [91] 0 0
LTU
Country [92] 0 0
Lithuania
State/province [92] 0 0
LT
Country [93] 0 0
Lithuania
State/province [93] 0 0
Jonava
Country [94] 0 0
Lithuania
State/province [94] 0 0
Kaunas
Country [95] 0 0
Lithuania
State/province [95] 0 0
Vilnius
Country [96] 0 0
Malaysia
State/province [96] 0 0
Kelantan
Country [97] 0 0
Malaysia
State/province [97] 0 0
Kuala Lumpur
Country [98] 0 0
Mexico
State/province [98] 0 0
Distrito Federal
Country [99] 0 0
Mexico
State/province [99] 0 0
Morelos
Country [100] 0 0
Mexico
State/province [100] 0 0
Aguascalientes
Country [101] 0 0
Mexico
State/province [101] 0 0
Durango
Country [102] 0 0
Mexico
State/province [102] 0 0
Querétaro
Country [103] 0 0
Norway
State/province [103] 0 0
Enebakk
Country [104] 0 0
Norway
State/province [104] 0 0
Fetsund
Country [105] 0 0
Norway
State/province [105] 0 0
Honefoss
Country [106] 0 0
Norway
State/province [106] 0 0
Oslo
Country [107] 0 0
Norway
State/province [107] 0 0
Spikkestad
Country [108] 0 0
Panama
State/province [108] 0 0
Panama City
Country [109] 0 0
Peru
State/province [109] 0 0
La Libertad
Country [110] 0 0
Peru
State/province [110] 0 0
Lima
Country [111] 0 0
Peru
State/province [111] 0 0
Arequipa
Country [112] 0 0
Philippines
State/province [112] 0 0
Metro Manila
Country [113] 0 0
Philippines
State/province [113] 0 0
Marikina City
Country [114] 0 0
Philippines
State/province [114] 0 0
Pasay City
Country [115] 0 0
Philippines
State/province [115] 0 0
Pasig City
Country [116] 0 0
Philippines
State/province [116] 0 0
San Juan City
Country [117] 0 0
Poland
State/province [117] 0 0
Poznan
Country [118] 0 0
Poland
State/province [118] 0 0
Wroclaw
Country [119] 0 0
Poland
State/province [119] 0 0
Zabrze
Country [120] 0 0
Romania
State/province [120] 0 0
Bihor
Country [121] 0 0
Romania
State/province [121] 0 0
Jud. Bihor
Country [122] 0 0
Romania
State/province [122] 0 0
Jud. Prahova
Country [123] 0 0
Romania
State/province [123] 0 0
Bucharest
Country [124] 0 0
Romania
State/province [124] 0 0
Bucuresti
Country [125] 0 0
Romania
State/province [125] 0 0
Timisoara
Country [126] 0 0
Russian Federation
State/province [126] 0 0
Moscow
Country [127] 0 0
Russian Federation
State/province [127] 0 0
N.Novgorod
Country [128] 0 0
Russian Federation
State/province [128] 0 0
Penza
Country [129] 0 0
Russian Federation
State/province [129] 0 0
Petrozavodsk
Country [130] 0 0
Russian Federation
State/province [130] 0 0
Ryazan
Country [131] 0 0
Russian Federation
State/province [131] 0 0
Saint Petersburg
Country [132] 0 0
Russian Federation
State/province [132] 0 0
Saratov
Country [133] 0 0
Russian Federation
State/province [133] 0 0
Smolensk
Country [134] 0 0
Russian Federation
State/province [134] 0 0
St-Petersburg
Country [135] 0 0
Russian Federation
State/province [135] 0 0
St.- Petersburg
Country [136] 0 0
Slovakia
State/province [136] 0 0
Slovak Republic
Country [137] 0 0
Slovakia
State/province [137] 0 0
Banska Bystrica
Country [138] 0 0
Slovakia
State/province [138] 0 0
Kosice
Country [139] 0 0
Slovakia
State/province [139] 0 0
Levice
Country [140] 0 0
Slovakia
State/province [140] 0 0
Nové Zámky
Country [141] 0 0
Slovakia
State/province [141] 0 0
Presov
Country [142] 0 0
Slovakia
State/province [142] 0 0
Sabinov
Country [143] 0 0
Slovakia
State/province [143] 0 0
Sered
Country [144] 0 0
Slovakia
State/province [144] 0 0
Sturovo
Country [145] 0 0
Slovakia
State/province [145] 0 0
Zilina
Country [146] 0 0
South Africa
State/province [146] 0 0
Alberton
Country [147] 0 0
South Africa
State/province [147] 0 0
Cape Town
Country [148] 0 0
South Africa
State/province [148] 0 0
Durban
Country [149] 0 0
South Africa
State/province [149] 0 0
Gauteng
Country [150] 0 0
South Africa
State/province [150] 0 0
Johannesburg
Country [151] 0 0
South Africa
State/province [151] 0 0
Pretoria
Country [152] 0 0
Spain
State/province [152] 0 0
Barcelona
Country [153] 0 0
Spain
State/province [153] 0 0
Cataluña
Country [154] 0 0
Taiwan
State/province [154] 0 0
Hsintien
Country [155] 0 0
Taiwan
State/province [155] 0 0
Taichung
Country [156] 0 0
Taiwan
State/province [156] 0 0
Taipei
Country [157] 0 0
Taiwan
State/province [157] 0 0
Taoyuan
Country [158] 0 0
Turkey
State/province [158] 0 0
Adana
Country [159] 0 0
Turkey
State/province [159] 0 0
Antalya
Country [160] 0 0
Turkey
State/province [160] 0 0
Denizli
Country [161] 0 0
Turkey
State/province [161] 0 0
Diskapi / Ankara
Country [162] 0 0
Turkey
State/province [162] 0 0
Istanbul
Country [163] 0 0
Turkey
State/province [163] 0 0
Izmir
Country [164] 0 0
Turkey
State/province [164] 0 0
Kahramanmaras

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Novartis Pharmaceuticals
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study was to determine whether the initiation of a vildagliptin plus metformin combination regimen would result in more durable glycemic control than metformin monotherapy in treatment-naïve patients with type-2 diabetes mellitus (T2DM).
Trial website
https://clinicaltrials.gov/study/NCT01528254
Trial related presentations / publications
Tsotra F, Kappel M, Peristeris P, Bader G, Levi E, Lister N, Malhotra A, Ostwald DA. The societal impact of early intensified treatment in patients with type 2 diabetes mellitus. J Comp Eff Res. 2022 Nov;11(16):1185-1199. doi: 10.2217/cer-2022-0110. Epub 2022 Sep 28.
Vencio S, Manosalva JP, Mathieu C, Proot P, Lozno HY, Paldanius PM. Exploring early combination strategy in Latin American patients with newly diagnosed type 2 diabetes: a sub-analysis of the VERIFY study. Diabetol Metab Syndr. 2021 Jun 15;13(1):68. doi: 10.1186/s13098-021-00686-9.
Matthews D, Del Prato S, Mohan V, Mathieu C, Vencio S, Chan JCN, Stumvoll M, Paldanius PM. Insights from VERIFY: Early Combination Therapy Provides Better Glycaemic Durability Than a Stepwise Approach in Newly Diagnosed Type 2 Diabetes. Diabetes Ther. 2020 Nov;11(11):2465-2476. doi: 10.1007/s13300-020-00926-7. Epub 2020 Sep 25.
Matthews DR, Paldanius PM, Proot P, Chiang Y, Stumvoll M, Del Prato S; VERIFY study group. Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial. Lancet. 2019 Oct 26;394(10208):1519-1529. doi: 10.1016/S0140-6736(19)32131-2. Epub 2019 Sep 18.
Matthews DR, Paldanius PM, Proot P, Foley JE, Stumvoll M, Del Prato S. Baseline characteristics in the VERIFY study: a randomized trial assessing the durability of glycaemic control with early vildagliptin-metformin combination in newly diagnosed Type 2 diabetes. Diabet Med. 2019 Apr;36(4):505-513. doi: 10.1111/dme.13886. Epub 2019 Feb 12.
Public notes

Contacts
Principal investigator
Name 0 0
Novartis Pharmaceuticals
Address 0 0
Novartis Pharmaceuticals
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT01528254